PE20201282A1 - Derivados de piridinona y su uso como inhibidores selectivos de alk-2 - Google Patents
Derivados de piridinona y su uso como inhibidores selectivos de alk-2Info
- Publication number
- PE20201282A1 PE20201282A1 PE2020000516A PE2020000516A PE20201282A1 PE 20201282 A1 PE20201282 A1 PE 20201282A1 PE 2020000516 A PE2020000516 A PE 2020000516A PE 2020000516 A PE2020000516 A PE 2020000516A PE 20201282 A1 PE20201282 A1 PE 20201282A1
- Authority
- PE
- Peru
- Prior art keywords
- alk
- compound
- 6alkyl
- selective inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a un compuesto de formula I, o una de sus sales farmaceuticamente aceptable, en donde A representa a A.1 o A.2; R1 es H, C1-4alquilo o C1-4alcoxi; R2 y R3 es independientemente H, C1-6alquilo, C1-6haloalquilo, entre otros; X es N o -CH; R4 es H, o amino; Y es N o -CR5; R5 es H o F; Z es N o -CR9; n es 0, 1 o 2; W es -C(=O)- o -S(O)2-; R6 y R7 son independientemente H, F, o C1-4 alquilo; R8 es H, C1-6alquilo, C3-6cicloalquiloC1-6alquilo, entre otros. Un compuesto preferido es 5-(5-(1-isopropil-6-oxo-1,6-dihidropiridin-3-il)piridin-3-il)-1-metilindolin-2-ona. Estos compuestos son inhibidores selectivos de alk-2. como inhibidores selectivos de alk-2Tambien se refiere a una composicion farmaceutica que comprende una cantidad terapeuticamente eficaz de dicho compuesto, fabricacion de un medicamento que comprende dicho compuesto y su uso en el tratamiento de anemia cronica, osificacion heterotopica, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2017/057389 WO2019102256A1 (en) | 2017-11-24 | 2017-11-24 | Pyridinone derivatives and their use as selective alk-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201282A1 true PE20201282A1 (es) | 2020-11-24 |
Family
ID=60702886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000516A PE20201282A1 (es) | 2017-11-24 | 2017-11-24 | Derivados de piridinona y su uso como inhibidores selectivos de alk-2 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11160797B2 (es) |
| EP (1) | EP3713927B1 (es) |
| JP (1) | JP7091455B2 (es) |
| KR (1) | KR20200091422A (es) |
| CN (1) | CN111433195B (es) |
| AU (1) | AU2017440306B2 (es) |
| BR (1) | BR112020010171A2 (es) |
| CA (1) | CA3081651A1 (es) |
| CL (1) | CL2020001277A1 (es) |
| CO (1) | CO2020005885A2 (es) |
| CR (1) | CR20200211A (es) |
| CU (1) | CU20200035A7 (es) |
| DO (1) | DOP2020000088A (es) |
| EA (1) | EA202091293A1 (es) |
| EC (1) | ECSP20026023A (es) |
| ES (1) | ES2908252T3 (es) |
| IL (1) | IL274722A (es) |
| JO (1) | JOP20200127A1 (es) |
| MX (1) | MX2020005405A (es) |
| PE (1) | PE20201282A1 (es) |
| PH (1) | PH12020550763A1 (es) |
| RU (1) | RU2020120538A (es) |
| SG (1) | SG11202003920QA (es) |
| WO (1) | WO2019102256A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220401445A1 (en) * | 2020-04-30 | 2022-12-22 | Keros Therapeutics, Inc. | Methods of using alk2 inhibitors |
| CN113354631B (zh) * | 2021-06-01 | 2022-11-18 | 江苏大学 | 一种1,3,4-噁二唑衍生物及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316217B1 (en) | 1992-11-17 | 2001-11-13 | Ludwig Institute For Cancer Research | Activin receptor-like kinases, proteins having serine threonine kinase domains and polynucleotides encoding same |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US8895711B2 (en) | 2006-04-18 | 2014-11-25 | The Trustees Of The University Of Pennsylvania | Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP) |
| KR20090088852A (ko) | 2006-09-05 | 2009-08-20 | 메다렉스, 인코포레이티드 | 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법 |
| EP2062048A4 (en) | 2006-09-12 | 2009-12-02 | Gen Hospital Corp | METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE CELL SIGNALING AND METHODS EMPLOYING SUCH COMPOUNDS |
| JP5638961B2 (ja) | 2008-03-13 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | Ｂｍｐシグナル伝達経路のインヒビター |
| MX2012012975A (es) * | 2010-05-07 | 2013-02-26 | Genentech Inc | Compuestos de piridona y aza-piridona y metodos de uso de los mismos. |
| EP2605787B1 (en) | 2010-08-20 | 2017-04-26 | Wyeth LLC | Designer osteogenic proteins |
| MX2013006284A (es) | 2010-12-06 | 2013-10-28 | Piramal Entpr Ltd | Derivados sustituidos de imidazoquinolina. |
| ES2857649T3 (es) | 2012-03-01 | 2021-09-29 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| EP3122355A4 (en) * | 2014-03-26 | 2017-08-09 | The Brigham and Women's Hospital, Inc. | Compositions and methods for inhibiting bmp |
| US20170305883A1 (en) * | 2014-10-01 | 2017-10-26 | The Brigham And Women's Hospital, Inc. | Compositions and Methods for Inhibiting BMP |
| ES2766835T3 (es) * | 2015-04-16 | 2020-06-15 | Merck Patent Gmbh | Derivados de 3-(1H-bencimidazol-2-il)-1H-piridin-2-ona |
-
2017
- 2017-11-24 CU CU2020000035A patent/CU20200035A7/es unknown
- 2017-11-24 EP EP17817144.3A patent/EP3713927B1/en active Active
- 2017-11-24 US US16/766,114 patent/US11160797B2/en active Active
- 2017-11-24 MX MX2020005405A patent/MX2020005405A/es unknown
- 2017-11-24 EA EA202091293A patent/EA202091293A1/ru unknown
- 2017-11-24 WO PCT/IB2017/057389 patent/WO2019102256A1/en unknown
- 2017-11-24 SG SG11202003920QA patent/SG11202003920QA/en unknown
- 2017-11-24 KR KR1020207017240A patent/KR20200091422A/ko not_active Application Discontinuation
- 2017-11-24 PE PE2020000516A patent/PE20201282A1/es unknown
- 2017-11-24 CN CN201780097129.0A patent/CN111433195B/zh active Active
- 2017-11-24 BR BR112020010171-0A patent/BR112020010171A2/pt not_active IP Right Cessation
- 2017-11-24 AU AU2017440306A patent/AU2017440306B2/en not_active Ceased
- 2017-11-24 CR CR20200211A patent/CR20200211A/es unknown
- 2017-11-24 CA CA3081651A patent/CA3081651A1/en not_active Abandoned
- 2017-11-24 ES ES17817144T patent/ES2908252T3/es active Active
- 2017-11-24 RU RU2020120538A patent/RU2020120538A/ru unknown
- 2017-11-24 JP JP2020528328A patent/JP7091455B2/ja active Active
- 2017-11-24 JO JOP/2020/0127A patent/JOP20200127A1/ar unknown
-
2020
- 2020-05-12 PH PH12020550763A patent/PH12020550763A1/en unknown
- 2020-05-13 EC ECSENADI202026023A patent/ECSP20026023A/es unknown
- 2020-05-14 DO DO2020000088A patent/DOP2020000088A/es unknown
- 2020-05-14 CL CL2020001277A patent/CL2020001277A1/es unknown
- 2020-05-14 CO CONC2020/0005885A patent/CO2020005885A2/es unknown
- 2020-05-17 IL IL274722A patent/IL274722A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020120538A (ru) | 2021-12-24 |
| JP2021512850A (ja) | 2021-05-20 |
| AU2017440306B2 (en) | 2021-01-28 |
| CN111433195B (zh) | 2023-04-25 |
| RU2020120538A3 (es) | 2021-12-24 |
| ECSP20026023A (es) | 2020-07-31 |
| CA3081651A1 (en) | 2019-05-31 |
| JOP20200127A1 (ar) | 2020-05-21 |
| DOP2020000088A (es) | 2020-08-31 |
| CU20200035A7 (es) | 2021-03-11 |
| CN111433195A (zh) | 2020-07-17 |
| WO2019102256A1 (en) | 2019-05-31 |
| EP3713927A1 (en) | 2020-09-30 |
| MX2020005405A (es) | 2020-08-13 |
| CL2020001277A1 (es) | 2020-11-13 |
| EA202091293A1 (ru) | 2020-11-23 |
| US11160797B2 (en) | 2021-11-02 |
| EP3713927B1 (en) | 2021-12-15 |
| US20200360357A1 (en) | 2020-11-19 |
| AU2017440306A1 (en) | 2020-05-21 |
| SG11202003920QA (en) | 2020-06-29 |
| CO2020005885A2 (es) | 2020-07-31 |
| ES2908252T3 (es) | 2022-04-28 |
| BR112020010171A2 (pt) | 2020-11-03 |
| CR20200211A (es) | 2020-06-19 |
| JP7091455B2 (ja) | 2022-06-27 |
| PH12020550763A1 (en) | 2021-04-26 |
| KR20200091422A (ko) | 2020-07-30 |
| IL274722A (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190761A1 (es) | Inhibidores de procesos metabolicos celulares | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| AR102094A1 (es) | Inhibidores de proteínas kras con una mutación g12c | |
| PE20160044A1 (es) | Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos | |
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| AR078201A1 (es) | Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| PE20180457A1 (es) | Piridinas sustituidas y metodo de uso | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| AR084144A1 (es) | Compuestos y metodos para restaurar la piel | |
| EA201700504A1 (ru) | 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение | |
| AR051796A1 (es) | Derivados de hidantoina como inhibidores de metaloproteinasas | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| EA202191114A1 (ru) | Производные пиридинилсульфонамида, фармацевтические композиции и их применение | |
| EA201990343A1 (ru) | Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2 | |
| CO2020012353A2 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| PE20171335A1 (es) | Inhibidores de gingipaina de lisina | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina |